Trexquant Investment LP Grows Stock Holdings in AngioDynamics, Inc. $ANGO

Key Points

• Trexquant Investment LP increased its stake in AngioDynamics by 334.2% in the 1st quarter, owning 355,066 shares valued at approximately $3.33 million by the end of the quarter.
• AngioDynamics reported quarterly earnings of ($0.03) per share, outperforming estimates by $0.09, and showed a year-over-year revenue increase of 13.0% to $80.16 million.
• Analysts show a positive outlook, with multiple firms upgrading AngioDynamics to a "buy" rating and setting a consensus target price of $19.00.

Trexquant Investment LP lifted its holdings in shares of AngioDynamics, Inc. (NASDAQ:ANGO - Free Report) by 334.2% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 355,066 shares of the medical instruments supplier's stock after buying an additional 273,295 shares during the quarter. Trexquant Investment LP owned about 0.87% of AngioDynamics worth $3,334,000 at the end of the most recent quarter.

Other institutional investors also recently modified their holdings of the company. Squarepoint Ops LLC purchased a new stake in shares of AngioDynamics during the 4th quarter valued at approximately $387,000. Ameriprise Financial Inc. raised its position in shares of AngioDynamics by 24.0% during the 4th quarter. Ameriprise Financial Inc. now owns 277,565 shares of the medical instruments supplier's stock valued at $2,542,000 after buying an additional 53,675 shares in the last quarter. GAMMA Investing LLC raised its position in shares of AngioDynamics by 1,281.4% during the 1st quarter. GAMMA Investing LLC now owns 13,897 shares of the medical instruments supplier's stock valued at $130,000 after buying an additional 12,891 shares in the last quarter. GSA Capital Partners LLP purchased a new stake in shares of AngioDynamics during the 1st quarter valued at $642,000. Finally, New York State Common Retirement Fund raised its position in shares of AngioDynamics by 667.0% during the 1st quarter. New York State Common Retirement Fund now owns 54,635 shares of the medical instruments supplier's stock valued at $513,000 after buying an additional 47,512 shares in the last quarter. 89.43% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several analysts have recently weighed in on ANGO shares. HC Wainwright restated a "buy" rating and set a $16.00 price objective on shares of AngioDynamics in a research report on Wednesday, July 16th. Lake Street Capital began coverage on shares of AngioDynamics in a research report on Wednesday, July 16th. They issued a "buy" rating and a $24.00 target price on the stock. Wall Street Zen upgraded shares of AngioDynamics from a "hold" rating to a "buy" rating in a research report on Saturday, August 16th. Finally, Canaccord Genuity Group lifted their target price on shares of AngioDynamics from $15.00 to $17.00 and gave the stock a "buy" rating in a research report on Wednesday, July 16th. Three research analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, the company presently has a consensus rating of "Buy" and an average target price of $19.00.

AngioDynamics Price Performance

NASDAQ ANGO traded up $0.07 during trading hours on Monday, reaching $10.80. 44,971 shares of the company's stock traded hands, compared to its average volume of 611,587. AngioDynamics, Inc. has a 52-week low of $5.83 and a 52-week high of $13.50. The firm has a market cap of $438.97 million, a PE ratio of -12.80 and a beta of 0.64. The firm has a 50-day simple moving average of $9.28 and a 200 day simple moving average of $9.55.

AngioDynamics (NASDAQ:ANGO - Get Free Report) last issued its quarterly earnings results on Tuesday, July 15th. The medical instruments supplier reported ($0.03) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.12) by $0.09. AngioDynamics had a negative net margin of 11.62% and a negative return on equity of 3.20%. The company had revenue of $80.16 million during the quarter, compared to analysts' expectations of $74.26 million. During the same period last year, the company posted ($0.06) EPS. AngioDynamics's revenue was up 13.0% on a year-over-year basis. AngioDynamics has set its FY 2026 guidance at -0.350--0.250 EPS. Sell-side analysts forecast that AngioDynamics, Inc. will post -0.37 EPS for the current fiscal year.

About AngioDynamics

AngioDynamics, Inc, a medical technology company, engages in the design, manufacture, and sale of medical, surgical, and diagnostic devices for the use in treating peripheral vascular disease, and oncology and surgical settings in the United States and internationally. The company offers Auryon Atherectomy system that is designed to deliver an optimized wavelength, pulse width, and amplitude to remove lesions while preserving vessel wall endothelium.